Yunnan Botanee Bio-Technology Group Co Ltd

Yunnan Botanee Bio-Technology Group Co Ltd maintains a strong liquidity position with a current ratio of 3.77, indicating the company can cover its short-term liabilities more than three times over. However, the company has a negative net cash position after subtracting total debt, which introduces some liquidity risk. The debt-to-equity ratio of 0.14 suggests a conservative capital structure with limited leverage. The company's profitability is reflected in a return on equity (ROE) of 8.21% and a return on assets (ROA) of 6.06%, both of which are in line with the industry's preferred metrics for personal products firms. The gross profit margin of 73.3% (calculated from gross profit of 3.93 billion CNY on revenue of 5.36 billion CNY) indicates strong cost control and pricing power. However, the operating margin of 11.75% (calculated from operating income of 628.93 million CNY) is lower, suggesting some pressure on operating expenses. The company's revenue is concentrated in the personal products segment, with no disclosed geographic diversification beyond China. This concentration increases exposure to domestic economic conditions and regulatory changes. The company's free cash flow is negative at -16.44 million CNY, indicating that capital expenditures are outpacing operating cash flow. Capital expenditures of 482.99 million CNY suggest a significant investment in growth or expansion. Looking ahead, the company is expected to maintain a stable revenue trajectory, with no significant growth or contraction projected in the current or next fiscal year. The company's risk assessment indicates a medium liquidity risk and a low dilution risk, with no immediate pressure for equity issuance. The negative net cash position after debt is a key flag to monitor. Recent events include analyst estimates with a mean price target of 44.51 CNY and a median of 44.00 CNY, indicating a generally positive outlook from the investment community. The mean recommendation of 2.27 (on a scale from 1 to 5) suggests a slight bias toward buy ratings, with four strong-buy and four buy recommendations.